Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.57 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | TCF7 | P36402 | 1/20 | 0.43 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378619 | 1.00 | CHEK1 (0.57) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL5343977 | 0.98 | CHEK1 (0.56) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL427409 | 0.84 | CHEK1 (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL30431594 | 0.84 | CHEK1 (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| Hydrochloric Acid SCHEMBL2481630 | 0.82 | MPO (0.44) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| Quinoline SCHEMBL27607112 | 0.82 | ALDH1A1 (0.54) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL18652292 | 0.81 | IRAK4 (0.51) | TRPA1SRCUSP7ARAPP | |
| SCHEMBL21568428 | 0.79 | VNN1 (0.54) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL15332949 | 0.79 | TRPA1 (0.46) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL424964 | 0.78 | TRPA1 (0.46) | CDC7TRPA1CTNNB1TCF7TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | claimed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025085233-A1 | NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4426688-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | Redx Pharma Plc (GB) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023079291-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2023-05-11 | — | — | WO | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | DDR1, DDR2, TGFBR2 | CHEK1 123/4885AURKA 2552/4885DAPK3 143/4885 |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, MPST, CRAT | CHEK1 3130/4885AURKA 2652/4885DAPK3 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.